drugset
drugset / Trial / NCT01535768

Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves

NCT01535768 ↗

Phase 4 Unknown 150 enrolled Credit Valley EyeCare Canadian Glaucoma Clinical Research Council · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

After implantation of an Ahmed glaucoma valve in patients with glaucoma, hyperencapsulation phase is an unwanted postoperative phenomenon, typically occurring with the free 3 months postoperatively. When this does occur, it is treated with aqueous suppressant eye drops. This study aims to determine if it is possible to reduce the rate of hyperencapsulation phase. Patients in the treatment group will receive aqueous suppressant eye drops before the hyperencapsulation phase starts. Treatment will be initiated once their intraocular pressure is above a pre-defined level, and will target a pre-defined range.

Timeline

Start
2012-02
Primary completion
2018-06
Completion
2020-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetazolamide Small molecule 250 mg Oral
Subject Bimatoprost Other / unclassified 0.01 % Topical
Subject Bimatoprost Other / unclassified 0.03 % Topical
Subject Brimonidine Small molecule 0.1 % Topical
Subject Brimonidine Small molecule 0.15 % Topical
Subject Brinzolamide Small molecule 1 % Topical
Subject Dorzolamide Small molecule 2 % Topical
Subject Latanoprost Small molecule 0.005 % Topical
Subject Timolol Other / unclassified 0.25 % Topical
Subject Timolol Other / unclassified 0.5 % Topical
Subject Travoprost Other / unclassified 0.004 % Topical

Indications

glaucoma